Annotation Detail
Information
- Associated Genes
- FGFR1
- Associated Variants
- FGFR1 FGFR1 FUSIONS FGFR1 FGFR1 FUSIONS
- Associated Disease
- acute myeloid leukemia
- Source Database
- CIViC Evidence
- Description
- In a preclinical trial, the AML cell line KG1 with the FGFR1OP2-FGFR1 fusion mutation was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was much more effective in the growth inhibition of cells harboring the fusion mutation (IC50=17 nmol/L) compared to sorafenib (IC50>100 nmol/L) and sunitinib (IC50>100 nmol/L).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/7375
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1885
- Variant URL
- https://civic.genome.wustl.edu/links/variants/569
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Acute Myeloid Leukemia
- Evidence Direction
- Does Not Support
- Drug
- Sunitinib,Sorafenib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 21482694